Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® today announced that an abstract presenting results of two ...
Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...
Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting ...
JERUSALEM, March 09, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, ...
CLEVELAND, Ohio — The Ohio State University’s James Cancer Hospital has treated the world’s first brain cancer patient to receive a new radiation technology that attacks tumors from within, the ...
TOKYO--(BUSINESS WIRE)--HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT (Diffusing Alpha Radiation Therapy),’ developed by Alpha Tau ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results